|Day's Range||3.25 - 3.49|
|52 Week Range||3.01 - 7.15|
|PE Ratio (TTM)||-8.33|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The next generation of breast and ovarian cancer treatment is attacking the deadly disease from all angles. That is no more evident than in the glut of pharmaceutical companies racing to develop, test, ...
Click here to see latest analysisTapImmune, Inc. reports financial results for the quarter ended September 30, 2015.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD 2.48 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.TPIV-US‘s book value of equity is […] (Read more...) The post TapImmune, Inc. :TPIV-US: Earnings Analysis: Q3, 2015 By the Numbers appeared first on CapitalCube.
TapImmune, Inc. reports preliminary financial results for the quarter ended June 30, 2015.We analyze the earnings along side the following peers of TapImmune Inc. – Newlink Genetics Corporation, Progenics Pharmaceuticals, Inc., United Therapeutics Corporation, Opexa Therapeutics, Inc., Aeterna Zentaris Inc., Mirati Therapeutics Inc. and Sophiris Bio Inc. (NLNK-US, PGNX-US, UTHR-US, OPXA-US, AEZS-US, MRTX-US and SPHS-US) (Read more...) The post TapImmune, Inc. Earnings Q2, 2015 appeared first on CapitalCube.